Relmada Therapeutics Inc
Change company Symbol lookup
Select an option...
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025
CG Carlyle Group Inc
ETR Entergy Corp
SKIN Beauty Health Co
PYR Pyrogenesis Canada Inc
KHZM Madison Ave Media Inc
PEO Adams Natural Resources Fund
MF Missfresh Ltd

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

Closing Price
Day's Change
1.45 (4.56%)
B/A Size
Day's High
Day's Low

10-day average volume:

Digital World stock tumbles after SPAC buying Trump Media discloses another SEC subpoena

6:37 am ET June 13, 2022 (MarketWatch)

Shares of Digital World Acquisition Corp. (DWAC) tumbled 8.2% in premarket trading Monday, after the special purpose acquisition company (SPAC) that is buying the company behind Donald Trump's Truth Social said it received another subpoena from the Securities and Exchange Commission related to the acquisition. The SPAC said the subpoena seeks additional information on "communications regarding and due diligence of of potential targets other than TMTG" [Trump Media & Technology Group Corp.] and relationships between Digital World and certain advisors, shareholders, as well as certain forward-looking information about TMTG. The company said order of the examination of the registration statement "could materially delay, materially impede or prevent the consummation of the business combination." Digital World are previously disclosed in May a subpoena from the SEC seeking documents and information regarding several things, including meetings of the board of directors, the evaluation of potential acquisition targets including TMTG, communications relating to TMTG and payments made to certain advisors. The stock has plunged 38.6% over the past three months through Friday, while the S&P 500 has declined 7.2%.

-Tomi Kilgore


(END) Dow Jones Newswires

June 13, 2022 06:37 ET (10:37 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.